Is It Too Late To Consider Viatris (VTRS) After A 94% One-Year Share Price Surge [Yahoo! Finance]
Viatris Inc. (VTRS)
Company Research
Source: Yahoo! Finance
Investors may be wondering whether Viatris at US$14.01 still offers value after a strong run, or if most of the opportunity has already been priced in. The stock has recorded returns of 2.9% over the last 7 days, 1.5% over the last 30 days, 12.4% year to date, and 94.0% over the past year. Longer term 3 year and 5 year returns are 65.6% and 29.4% respectively. Recent coverage has focused on Viatris as a large, diversified pharmaceutical name, with attention on its product portfolio and progress on its broader corporate initiatives. That context helps explain how the share price has moved over the last year. On Simply Wall St's valuation checks, Viatris scores 5 out of 6 . The rest of this article will walk through the key valuation approaches behind that score, then finish with a way to look at valuation that can provide an even clearer picture. Viatris delivered 94.0% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry. Approach 1
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Theravance Biopharma: A Special Situation With A 50-100% Likely Upside [Seeking Alpha]Seeking Alpha
- Xanax XR recalled after discovery that tablets may fail to release medication properly [FOX Business Network]FOX Business Network
- Xanax from West Virginia-based company recalled nationwide. What you need to know [Los Angeles Times (CA)]Los Angeles Times
- Viatris to Report First Quarter 2026 Financial Results on May 7, 2026PR Newswire
- Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingPR Newswire
VTRS
Earnings
- 2/26/26 - Beat
VTRS
Sec Filings
- 4/16/26 - Form 4
- 4/2/26 - Form ARS
- 4/2/26 - Form DEFA14A
- VTRS's page on the SEC website